CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that 32 studies on the company’s INTERCEPT Blood System have been accepted for presentation at the International Congress of the International Society of Blood Transfusion to be held in Macao SAR, China, June 7-12, 2008. The studies reported include information on clinical experience from implementation of the INTERCEPT Blood System in routine practice, support of patients with severe congenital bleeding disorders undergoing major surgery, the inactivation of protozoa and Avian influenza virus, patient outcomes from hemovigilence surveillance programs for platelets and plasma, as well as results from clinical studies of the modified red blood cell system.
